• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Talphera Inc.

    9/16/25 2:11:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    TALPHERA, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00444T209

    (CUSIP Number)


    09/10/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00444T209


    1Names of Reporting Persons

    LYTTON LAURENCE W
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,636,364.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,636,364.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,636,364.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 20,522,655 shares of Common Stock outstanding as of August 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, and (b) 25,036,360 shares of Common Stock issued by the Issuer in a private placement on September 10, 2025, as reported in the Form 8-K filed by the Issuer on September 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    00444T209


    1Names of Reporting Persons

    Lytton-Kambara Foundation
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,636,364.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,636,364.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,636,364.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 20,522,655 shares of Common Stock outstanding as of August 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, and (b) 25,036,360 shares of Common Stock issued by the Issuer in a private placement on September 10, 2025, as reported in the Form 8-K filed by the Issuer on September 10, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TALPHERA, INC.
    (b)Address of issuer's principal executive offices:

    1850 Gateway Drive, Suite 175, San Mateo, CA 94404
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton and Lytton-Kambara Foundation ("Foundation").
    (b)Address or principal business office or, if none, residence:

    467 CENTRAL PARK WEST, NEW YORK, NY 10025
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00444T209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Lytton: 3,636,364 Foundation: 3,636,364
    (b)Percent of class:

    Lytton: 8.0% Foundation: 8.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Lytton: 0 Foundation: 0

     (ii) Shared power to vote or to direct the vote:

    Lytton: 3,636,364 Foundation: 3,636,364

     (iii) Sole power to dispose or to direct the disposition of:

    Lytton: 0 Foundation: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Lytton: 3,636,364 Foundation: 3,636,364

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    LYTTON LAURENCE W
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:Reporting Person
    Date:09/16/2025
     
    Lytton-Kambara Foundation
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:President
    Date:09/16/2025
    Get the next $TLPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

    CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif., Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the develo

    9/8/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Announces Strategic Minority Investment in Talphera

    BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (NASDAQ:TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing. Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad™ and for pre-launch preparations. Talphera is a specialty pharm

    9/8/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

    The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial. The enrollment of 17 patients is a milestone that was required to be achieved, and announced, as one of the conditions to close the se

    8/25/25 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    SEC Filings

    View All

    SEC Form 424B7 filed by Talphera Inc.

    424B7 - TALPHERA, INC. (0001427925) (Filer)

    9/29/25 4:43:37 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Talphera Inc.

    S-3 - TALPHERA, INC. (0001427925) (Filer)

    9/22/25 5:10:32 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Talphera Inc.

    SCHEDULE 13G - TALPHERA, INC. (0001427925) (Subject)

    9/16/25 2:11:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,517 units of Commom Stock, decreasing direct ownership by 9% to 48,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    5/21/25 6:57:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil was granted 15,000 units of Commom Stock, increasing direct ownership by 40% to 52,695 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:31:19 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N was granted 15,000 shares, increasing direct ownership by 56% to 42,011 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:30:21 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $TLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:28:23 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/26/25 6:52:05 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    12/6/24 6:05:05 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Financials

    Live finance-specific insights

    View All

    Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical

    8/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

    SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link

    8/7/25 4:35:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

    Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial res

    5/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)